



**TO:** Clearing Member Firms  
Chief Financial Officers  
Back Office Managers

**FROM:** CME Clearing

**ADVISORY #:** 20-335

**SUBJECT:** CME Group Risk Management Tools Enhancement

**DATE:** August 26, 2020

---

Effective Sunday, September 20 (trade date Monday, September 21) CME Group will enhance Access Manager functionality in the CME Group Risk Management Tools user interface. This enhancement will give Clearing Firm Risk Administrators the option to prevent new order entry at the Execution Firm level during the two-day period prior to expiration in the front-month contract of CL, CLT, CLL, and CLS. These are the only products in scope for this enhancement.

Currently, for a limited set of deliverable products (MAC Swap Futures, COMEX London Spot Gold and COMEX London Spot Silver) there is a restricted period prior to last trading day where new order entry is prohibited. Access Manager is used by clearing firms to manually permission (white-list) accounts that will be allowed submit new orders during the restricted period. Current positions and any outstanding orders already at the matching engine are not managed by this tool.

The enhancements are as follows:

- Use of the enhancements are optional
- Current order entry for the CL products listed above will not be impacted if risk managers choose to not update any new settings for this functionality
- Clearing Firm Risk Administrators can use Access Manager to restrict new order entry in the CL products at the Executing Firm level
- Clearing Firm Risk Administrators can use Access Manager to white list accounts for new order entry at restricted Execution Firms.
- Clearing Firm Risk Administrators should keep in mind their own execution desk Execution Firms and account numbers and white list where appropriate

Testing in New Release is now available.

Additional information about the enhancement will be made available in the [Risk Management Tools User Help system](#).

Please contact Certification [Support for Electronic Trading \(CSET\)](#) in the U.S. at +1 312 930 2322, in Europe at +44 20 3379 3803 or in Asia at +65 6593 5593 with any questions on testing in New Release.